# **The Regulatory Dynamics and Pharmacokinetic Persistence of Coenzyme Q10: Evaluating Endogenous Biosynthesis and the Potential for Feedback Inhibition**

The biochemical status of coenzyme Q10 (![][image1]), an essential lipid-soluble cofactor and antioxidant, represents a critical intersection of metabolic bioenergetics and clinical pharmacology. As a ubiquitous component of every cellular membrane, its role in the mitochondrial electron transport chain (ETC) and its function as a lipophilic antioxidant have prompted extensive research into its regulation, specifically concerning whether exogenous supplementation might inadvertently suppress the body's natural production capacity. The question of whether ![][image1] induces a downregulation of endogenous production—either during administration or as a lingering "rebound" effect after cessation—is fundamental to the safety and efficacy profiles of its use in both healthy populations and those suffering from metabolic or age-related pathologies.1

## **The Molecular Architecture and Functional Versatility of Ubiquinone**

Coenzyme Q, or ubiquinone, is a redox-active lipid composed of a fully substituted benzoquinone ring and a polyisoprenoid side chain. In humans, this side chain consists of ten isoprene units, hence the designation ![][image1], whereas other species exhibit varying lengths, such as ![][image2] in *Saccharomyces cerevisiae*, ![][image3] in *Escherichia coli*, and ![][image4] in rodents.2 The structure, formally identified as 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone, grants the molecule its unique ability to cycle between three oxidation states: the fully oxidized ubiquinone, the radical semiquinone intermediate (![][image5]), and the fully reduced ubiquinol (![][image6]).5

The primary physiological function of ![][image1] is its participation in the mitochondrial respiratory chain. Located within the inner mitochondrial membrane, it acts as a mobile electron carrier, relaying electrons from Complex I (NADH-ubiquinone oxidoreductase) and Complex II (succinate-ubiquinone oxidoreductase) to Complex III (ubiquinol-cytochrome c oxidoreductase). This electron transfer is coupled with the translocation of protons across the membrane, generating the electrochemical gradient necessary for ATP synthesis through oxidative phosphorylation.2 Beyond the canonical ETC, ![][image1] serves as a requisite electron acceptor for several other enzymes, including those involved in fatty acid ![][image7]\-oxidation, pyrimidine de novo biosynthesis, and the metabolism of amino acids such as proline and glycine.2

Extramitochondrially, ![][image1] is recognized as the only endogenously synthesized lipid-soluble antioxidant. In its reduced form, ubiquinol, it protects biological membranes and plasma lipoproteins from oxidative damage by directly scavenging lipid peroxyl radicals and regenerating other antioxidants, such as ![][image8]\-tocopherol (Vitamin E) and ascorbate (Vitamin C).5 This antioxidant capacity is particularly vital in the context of ferroptosis, a form of iron-dependent regulated cell death driven by lipid peroxidation. Recent research has identified Ferroptosis Suppressor Protein 1 (FSP1) as a ![][image9]\-dependent ![][image1] reductase that maintains the ubiquinol pool at the plasma membrane, providing a glutathione-independent defense against ferroptotic injury.14

| Cellular Location | Primary Function | Relevant Mechanisms |
| :---- | :---- | :---- |
| Inner Mitochondrial Membrane | Electron Transport / ATP Synthesis | Complex I/II to III; Protol motive force generation |
| Mitochondrial Matrix | Metabolic Cofactor | ![][image7]\-oxidation; Pyrimidine synthesis; Amino acid catabolism |
| Plasma Membrane | Antioxidant / Ferroptosis Defense | FSP1-mediated ![][image1] reduction; Lipid peroxide scavenging |
| Lysosomal Membrane | pH Maintenance | Proton transport to maintain acidic digestive environment |
| Plasma Lipoproteins | Antioxidant Protection | Inhibition of LDL/VLDL oxidation; Synergy with Vitamin E |

The diversity of these roles underscores why a potential downregulation of endogenous synthesis would have profound implications for cellular health. If the body were to reduce its internal production in response to external intake, the delicate balance of ![][image1] segmentation—wherein specific pools are sequestered for different functions—could be disrupted.4

## **Endogenous Biosynthesis: The Mevalonate Trunk and the COQ Protein Complex**

All animal cells possess the capacity to synthesize ![][image1] endogenously, as the molecule is too hydrophobic to be efficiently distributed as an essential nutrient across all tissues from dietary sources alone.1 The biosynthetic process is a multi-stage assembly involving at least eleven known genes (![][image10] through ![][image11]) and their corresponding proteins, which predominantly localize to the mitochondrial matrix or the matrix face of the inner mitochondrial membrane.2

The pathway is bifurcated into the synthesis of the polyisoprenoid tail and the benzoquinone head group. The tail is constructed via the mevalonate pathway, which also produces cholesterol, dolichols, and heme A.5 The rate-limiting step of this shared trunk is catalyzed by 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), which converts HMG-CoA into mevalonate. HMGCR is the primary target of statin medications, which explains the observed decline in ![][image1] levels among patients treated with these drugs.11 Once the pathway reaches the production of farnesyl pyrophosphate (FPP), it branches; the PDSS1/PDSS2 enzyme complex (also known as ![][image10]) then catalyzes the addition of seven more isoprene units to FPP to form the decaprenyl diphosphate tail.2

Simultaneously, the benzoquinone head group is synthesized from the aromatic amino acids tyrosine or phenylalanine, which are converted into 4-hydroxybenzoate (4-HB). In some instances, para-aminobenzoic acid (pABA) can also serve as a precursor.5 The pivotal condensation step, which links the 10-unit isoprenoid tail to the 4-HB ring, is performed by the ![][image12]\-encoded enzyme, polyprenyl transferase.2

Following condensation, the intermediate (3-decaprenyl-4-hydroxybenzoic acid) undergoes a series of modifications orchestrated by a high-molecular-weight multi-protein complex known as the ![][image13]\-synthome. This complex ensures the efficiency and regioselectivity of the chemical transformations, which include C-hydroxylations, O-methylations, C-decarboxylation, and C-methylations.2

### **The Role of Regulatory COQ Proteins**

* **COQ3**: An S-adenosylmethionine (SAM)-dependent O-methyltransferase that catalyzes two separate O-methylation steps in the pathway.2  
* **COQ4**: A structural protein that likely acts as a scaffold for the assembly and stabilization of the multi-protein complex.3  
* **COQ5**: A SAM-dependent C-methyltransferase responsible for the methylation of the quinone ring.2  
* **COQ6**: A flavin-dependent monooxygenase that hydroxylates the ring at the C5 position.2  
* **COQ7**: A carboxylate-bridged di-iron monooxygenase that performs the final hydroxylation step. Its phosphorylation state, regulated by the phosphatase Ptc7p (in yeast), is a key control point for the rate of ![][image13] synthesis.2  
* **COQ8 (ADCK3/4)**: A protein with kinase activity (though its exact substrate is debated) that is essential for the stability and phosphorylation of other ![][image14] subunits. Overexpression of ![][image15] has been shown to stabilize the biosynthetic complex in deficient models.2  
* **COQ9**: A lipid-binding protein that associates with ![][image16] and is required for its function and stability.2

This structural interdependence is critical: the absence or mutation of a single ![][image14] protein leads to the degradation of several other subunits, effectively halting endogenous production.18 This "all-or-nothing" assembly suggests that regulation is centralized at the level of complex stability rather than being a simple linear chain of independent reactions.

## **Regulatory Hierarchy and the Feedback Inhibition Hypothesis**

The primary concern regarding exogenous ![][image1] is whether high circulating levels can signal the cell to downregulate this sophisticated biosynthetic machinery. In many biological systems, such as the production of hormones (e.g., testosterone) or metabolites (e.g., cholesterol), exogenous administration triggers a negative feedback loop to maintain homeostasis. However, ![][image1] regulation appears to operate through distinct principles.33

### **Cholesterol vs. CoQ10: Contrasting Feedback Loops**

In cholesterol metabolism, the cell employs the SREBP2-SCAP-INSIG system to sense sterol levels in the endoplasmic reticulum. When cholesterol is abundant, it binds to SCAP, anchoring the SREBP2 transcription factor in the ER and preventing its translocation to the Golgi and nucleus. This results in the downregulation of HMGCR and other cholesterogenic genes.22

In contrast, no such end-product feedback sensor has been identified for ![][image1] in mammalian cells. Instead of being inhibited by ubiquinone, the biosynthetic pathway is regulated by metabolic demands and stress signals.1

| Regulatory Factor | Role in CoQ10​ Synthesis | Context / Stimulus |
| :---- | :---- | :---- |
| **PPAR$\\alpha$** | Upregulates biosynthetic genes | Cold exposure; Peroxisomal induction; Fatty acid oxidation 1 |
| **RXR$\\alpha$** | Involved in basal synthesis | General cellular homeostasis and development 1 |
| **NF\-![][image17]B** | Transcriptional regulator | Human cell culture response to stress 5 |
| **CLUH** | RNA-binding protein | Post-transcriptional control of ![][image18] transcripts 5 |
| **AMPK** | Metabolic sensor | Activation leads to upregulation of mevalonate/CoQ pathway 35 |

The lack of a direct inhibitory effect from exogenous ![][image1] is supported by multiple pharmacokinetic and clinical studies. Research has consistently shown that exogenous supplementation does not influence the expression of endogenous ![][image4] or ![][image1] biosynthetic genes.33 In fact, in certain pathological states like Familial Hypercholesterolemia (FH), exogenous ![][image1] has been shown to *restore* proper feedback inhibition of the cholesterol branch without dampening the ![][image13] branch, effectively correcting a dysregulated mevalonate pathway.35

## **Pharmacokinetic Evidence of Biosynthetic Independence**

The most robust evidence against the downregulation of ![][image1] production comes from longitudinal pharmacokinetic studies and the evaluation of "washout" periods. If exogenous ![][image1] induced a downregulation of endogenous production, stopping the substance would theoretically result in a "rebound deficiency"—a period where plasma and tissue levels drop significantly below the pre-supplementation baseline as the body struggles to restart its own production.

### **The Washout Phenomenon**

Numerous clinical trials have utilized washout periods to ensure that the effects of a treatment phase do not carry over. The consistent finding across these studies is that ![][image1] levels return to their original, individual baseline within a predictable timeframe, typically ranging from two to four weeks.36

| Study Population | Dose and Duration | Washout Period | Resulting Plasma Levels |
| :---- | :---- | :---- | :---- |
| Healthy Adults | 300 mg/day for 28 days | 14–21 days | Returned to near presupplementation values 38 |
| Elderly (65–74 yrs) | 100 mg (single dose) | 7 days | Returned to baseline before next crossover phase 37 |
| Healthy Volunteers | 150 mg/day for 14 days | 14 days | Returned to baseline 36 |
| CAD Patients | 300 mg/day for 12 weeks | N/A | Sustained elevation during use; no reported rebound 40 |

In a representative study involving exercise-trained individuals, the administration of 300 mg per day of ubiquinol for 28 days elevated blood ![][image1] levels approximately 10-fold above baseline. Following a 14-to-21-day washout period, these levels returned to their exact original baseline.38 This precise return to pre-study levels is a hallmark of biosynthetic independence; if the body's internal production had been suppressed, the levels would have reached a nadir below the baseline during the washout.

### **Accumulation and Cessation**

Further evidence suggests that ![][image1] does not accumulate in tissues or plasma in a way that permanently alters the homeostatic set point. Studies in both animals and humans have confirmed that while supplementation can increase levels in the blood, liver, and to some extent, the heart and skeletal muscle (if doses are sufficiently high), these levels do not persist after the exogenous supply is removed.16 The primary route of elimination is biliary and fecal, with a very small fraction excreted in urine, indicating that the body efficiently clears excess ![][image1] rather than using it to signal a permanent reduction in synthesis.25

## **Biological Rationale for the Absence of Rebound Deficiency**

The biological resilience of the ![][image1] biosynthetic pathway can be attributed to several factors inherent in its cellular role and distribution.

1. **Tissue-Specific Satiety and Saturation**: Mitochondria appear to maintain a "saturation level" for ![][image1]. In tissues with unimpaired synthetic capacity, ![][image1] reaches a plateau where further supplementation does not increase tissue levels beyond a certain point.16 This saturation likely prevents the buildup of "excess" internal levels that might otherwise trigger a feedback response.  
2. **Segmentation of Pools**: As previously discussed, ![][image1] is segmented into bound and free pools. Endogenous synthesis is closely coupled to the formation of mitochondrial supercomplexes. Exogenous ![][image1], while able to increase the "free pool" available for antioxidant functions, may not easily displace the endogenously produced ![][image1] that is already integrated into the respiratory chain machinery.4  
3. **Metabolic Demand-Driven Synthesis**: Because ![][image1] is required for the most fundamental aspect of cellular life—ATP production—the "cost" of shutting down internal production based on fluctuating external availability (dietary or supplemental) would be evolutionarily disadvantageous. Cells prioritize the continuous operation of the ETC over the energy savings of suppressing synthesis.  
4. **Lack of Centralized Endocrine Regulation**: ![][image1] is produced by virtually every cell in the body for its own use. Unlike the thyroid or adrenal glands, there is no centralized master gland that monitors systemic ![][image1] levels and sends a global "stop" signal to all tissues. Regulation is local and mitochondrial-centric.2

## **Aging, Statins, and Secondary Deficiencies: Restoring vs. Suppressing**

The discussion of downregulation must be nuanced when considering populations that already exhibit a deficit in ![][image1]. In these cases, supplementation is not overriding a healthy system but rather compensating for an existing insufficiency.

### **Age-Related Decline**

![][image1] levels are known to decline significantly with age. In humans, the highest tissue concentrations are typically found at age 20, with a steady decrease thereafter. By age 80, myocardial ![][image1] levels may be reduced to half of their peak values.7 This decline is thought to be a consequence of reduced biosynthetic enzyme activity and increased oxidative stress rather than a programmed feedback response.11

In elderly populations, supplementation has been shown to have profound long-term benefits. The Kise-10 study provided four years of ![][image1] and selenium supplementation to healthy elderly participants. Remarkably, a 10-year follow-up showed that the reduction in cardiovascular mortality persisted six years *after* the supplementation period had ended.42 This suggests that ![][image1] supplementation may actually help preserve or "re-prime" mitochondrial function rather than inducing a dependency or downregulation.

### **Statin-Induced Suppression**

Statins effectively "induce downregulation" of ![][image1], but they do so by inhibiting the mevalonate pathway, not through ![][image1]\-mediated feedback.24 Studies have consistently shown that statins reduce circulating ![][image1] concentrations by approximately 40% to 50%.25

| Medication / Condition | Mechanism of CoQ10​ Reduction | Effect of Supplementation |
| :---- | :---- | :---- |
| **Statins** | Inhibition of HMG-CoA Reductase (Mevalonate Pathway) | Reverses statin-induced depletion in blood 24 |
| **Aging** | Reduced enzymatic activity; Mitochondrial dysfunction | Improves bioenergetics and antioxidant capacity 11 |
| **Primary Deficiency** | Genetic mutations in ![][image14] genes | Acts as critical replacement therapy; saves lives 18 |
| **Atherosclerosis** | Mevalonate pathway dysregulation; Oxidative stress | May upregulate the biosynthetic pathway via AMPK 35 |

In the context of statin therapy, exogenous ![][image1] acts to restore levels back toward normal physiological ranges. Research indicates that this supplementation does not interfere with the statin's primary goal of lowering cholesterol and does not further inhibit the body's already-impaired ability to produce ![][image1].24

## **Safety Profile and Toxicity Evaluation**

The safety of ![][image1] has been extensively evaluated through various toxicological models. The Acceptable Daily Intake (ADI) is calculated at 12 mg/kg/day, based on a No-Observed-Adverse-Effect Level (NOAEL) of 1,200 mg/kg/day derived from chronic 52-week toxicity studies in rats.34 For a 70 kg adult, this equates to roughly 840 mg per day, though human trials have demonstrated safety at doses as high as 1,200 mg to 3,600 mg per day.33

The most frequent adverse effects are mild gastrointestinal symptoms, such as nausea, heartburn, or diarrhea, which do not show a dose-response relationship—meaning they are as likely at low doses as they are at high doses.33 Importantly, no studies have reported liver toxicity or permanent endocrine disruption following long-term use. The German Federal Institute for Risk Assessment (BfR) and the European Food Safety Authority (EFSA) maintain that ![][image1] is well-tolerated by the general healthy population, though caution is advised for specific groups like those on warfarin (due to structural similarity to Vitamin K) or those with biliary obstruction.11

## **Clinical Implications of ![][image1] Homeostasis**

Understanding that endogenous production remains active during supplementation has significant implications for clinical practice:

1. **Maintenance of Efficacy**: Because the body continues its own production, the "effective dose" for a patient is the sum of their endogenous synthesis plus the supplemental amount. This allows for stable ![][image1] status even with fluctuations in dietary intake.  
2. **No Need for "Cycling"**: Unlike certain performance-enhancing substances or hormones that require "off-cycles" to allow the body's natural production to recover, ![][image1] can be taken continuously without the risk of long-term suppression.  
3. **Role in Primary Deficiencies**: In patients with primary ![][image1] deficiency—where genetic mutations prevent adequate synthesis—supplementation is a permanent replacement therapy. These patients do not have a "natural production" to downregulate, and the external supply is their only source of this vital cofactor.18  
4. **Mitohormesis and Aging**: The fact that ![][image1] levels decline with age, combined with the lack of feedback inhibition, suggests that supplementation in the elderly is a logical strategy to counteract a natural metabolic decay. The "mitohormesis" hypothesis suggests that the body's response to ![][image1] levels (or the lack thereof) can trigger adaptive longevity pathways, and maintaining ![][image1] levels may help sustain these beneficial responses.8

## **Second and Third-Order Insights: The Broader Biological Impact**

Beyond the immediate question of downregulation, the data suggests deeper insights into the cellular logic of ![][image1]:

* **Epigenetic and Signaling Modulation**: Emergent research indicates that ![][image1] is not merely a passive electron carrier but a modulator of gene expression. It influences genes involved in inflammatory responses, lipid metabolism, and cellular signaling (e.g., ![][image19]\-![][image20], ![][image21], ![][image22]).1 This suggests that the "benefits" of ![][image1] might outlast its physical presence in the body by inducing favorable shifts in the cellular transcriptome.  
* **The ER-Mitochondria Connection**: Evidence suggests that ![][image13] synthesis might not be exclusively mitochondrial. The existence of ![][image12] homologs in the Golgi and the role of the Endoplasmic Reticulum-Mitochondria Encounter Structure (ERMES) in moving ![][image13] precursors suggest a highly distributed and resilient production network.2 This decentralization further explains why a systemic "signal" would be insufficient to downregulate production across all organelles.  
* **Protection Against Ferroptosis**: The discovery of FSP1 and the ![][image1] cycle at the plasma membrane recontextualizes ![][image1] as a fundamental survival factor. The body's refusal to downregulate ![][image1] may be a "fail-safe" against accidental ferroptotic triggers, ensuring that even if energy demands are low, the antioxidant defenses remain high.14

## **Conclusions**

Based on an exhaustive review of pharmacokinetic data, molecular regulatory pathways, and clinical trial results, there is no evidence that Coenzyme Q10 induces a downregulation of endogenous production during or after the cessation of the substance. The body's biosynthetic machinery, centered on the mitochondrial ![][image13]\-synthome, is governed by metabolic demand and oxidative stress rather than by end-product inhibition. Pharmacokinetic "washout" studies demonstrate a precise return to pre-supplementation baseline levels within two to four weeks, confirming that internal synthesis remains active throughout the period of administration. Furthermore, the absence of "rebound deficiency" across decades of clinical use supports the high safety profile and biological resilience of ![][image1] homeostasis. Supplementation, therefore, represents a viable long-term strategy to address the natural declines associated with aging or the pharmacological suppression induced by statins, without the risk of dampening the body's innate ability to synthesize this essential cofactor for life.

#### **Works cited**

1. Regulation of coenzyme Q biosynthesis and breakdown \- PubMed, accessed February 6, 2026, [https://pubmed.ncbi.nlm.nih.gov/14695916/](https://pubmed.ncbi.nlm.nih.gov/14695916/)  
2. Biochemistry of Mitochondrial Coenzyme Q Biosynthesis \- PMC \- NIH, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5731490/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5731490/)  
3. The Regulation of Coenzyme Q Biosynthesis in Eukaryotic Cells: All ..., accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4112530/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4112530/)  
4. Metabolic Targets of Coenzyme Q10 in Mitochondria \- PMC \- NIH, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8066821/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8066821/)  
5. Coenzyme Q biochemistry and biosynthesis \- PMC, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10106368/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10106368/)  
6. Coenzyme Q10 \- Wikipedia, accessed February 6, 2026, [https://en.wikipedia.org/wiki/Coenzyme\_Q10](https://en.wikipedia.org/wiki/Coenzyme_Q10)  
7. The Use of Coenzyme Q10 in Cardiovascular Diseases \- MDPI, accessed February 6, 2026, [https://www.mdpi.com/2076-3921/10/5/755](https://www.mdpi.com/2076-3921/10/5/755)  
8. The Paradox of Coenzyme Q10 in Aging \- PMC, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6770889/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6770889/)  
9. Identification of Coq11, a New Coenzyme Q Biosynthetic Protein in the CoQ-Synthome in Saccharomyces cerevisiae \- NIH, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4367260/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4367260/)  
10. Full article: Potential role of coenzyme Q10 in health and disease conditions, accessed February 6, 2026, [https://www.tandfonline.com/doi/full/10.2147/NDS.S112119](https://www.tandfonline.com/doi/full/10.2147/NDS.S112119)  
11. Coenzyme Q10 | Linus Pauling Institute | Oregon State University, accessed February 6, 2026, [https://lpi.oregonstate.edu/mic/dietary-factors/coenzyme-Q10](https://lpi.oregonstate.edu/mic/dietary-factors/coenzyme-Q10)  
12. Coenzyme Q10 Supplementation in Aging and Disease \- Frontiers, accessed February 6, 2026, [https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2018.00044/full](https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2018.00044/full)  
13. Coenzyme Q10: Is There a Clinical Role and a Case for Measurement? \- PMC, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC2533152/](https://pmc.ncbi.nlm.nih.gov/articles/PMC2533152/)  
14. Ferroptosis in Cancer and Inflammatory Diseases: Mechanisms and Therapeutic Implications \- PMC \- PubMed Central, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12409078/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12409078/)  
15. Harnessing the gut microbiome to modulate ferroptosis: a metabolic strategy for the treatment of digestive tract cancers \- PMC, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12641001/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12641001/)  
16. Coenzyme Q10 Therapy \- PMC \- NIH, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4112525/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4112525/)  
17. Modulation of Coenzyme Q10 content and oxidative status in human dermal fibroblasts using HMG-CoA reductase inhibitor over a broad range of concentrations. From mitohormesis to mitochondrial dysfunction and accelerated aging \- NIH, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6535058/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6535058/)  
18. The efficacy of coenzyme Q10 treatment in alleviating the symptoms of primary coenzyme Q10 deficiency \- medRxiv, accessed February 6, 2026, [https://www.medrxiv.org/content/10.1101/2022.05.21.22275418v1.full.pdf](https://www.medrxiv.org/content/10.1101/2022.05.21.22275418v1.full.pdf)  
19. Association between genetic variants in the Coenzyme Q10 metabolism and Coenzyme Q10 status in humans \- PMC \- PubMed Central, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC3160390/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3160390/)  
20. (PDF) Identification of Coq11, a New Coenzyme Q Biosynthetic Protein in the CoQ-Synthome in Saccharomyces cerevisiae \- ResearchGate, accessed February 6, 2026, [https://www.researchgate.net/publication/271597080\_Identification\_of\_Coq11\_a\_New\_Coenzyme\_Q\_Biosynthetic\_Protein\_in\_the\_CoQ-Synthome\_in\_Saccharomyces\_cerevisiae](https://www.researchgate.net/publication/271597080_Identification_of_Coq11_a_New_Coenzyme_Q_Biosynthetic_Protein_in_the_CoQ-Synthome_in_Saccharomyces_cerevisiae)  
21. Disorders of Human Coenzyme Q10 Metabolism: An Overview \- PMC, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7555759/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7555759/)  
22. The Contribution of Cholesterol and Squalene Synthase in Cancer: Molecular Mechanisms, Lipid Rafts and Therapeutic Approaches \- PMC, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12865258/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12865258/)  
23. Transferrin, insulin, and progesterone modulate intracellular concentrations of coenzyme Q and cholesterol, products of the mevalonate pathway, in undifferentiated PC12 cells \- PMC \- NIH, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10209592/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10209592/)  
24. coenzyme q10 treatment: Topics by Science.gov, accessed February 6, 2026, [https://www.science.gov/topicpages/c/coenzyme+q10+treatment.html](https://www.science.gov/topicpages/c/coenzyme+q10+treatment.html)  
25. Coenzyme Q10 \- PMC \- NIH, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6822644/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6822644/)  
26. HMG-CoA reductase inhibitors and coenzyme Q10 \- PubMed, accessed February 6, 2026, [https://pubmed.ncbi.nlm.nih.gov/15705257/](https://pubmed.ncbi.nlm.nih.gov/15705257/)  
27. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q \- COQ10 in New Zealand, accessed February 6, 2026, [https://www.coq10.co.nz/PDF/Biofactors\_and\_Statins.pdf](https://www.coq10.co.nz/PDF/Biofactors_and_Statins.pdf)  
28. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q 10 . A review of animal and human publications \- ResearchGate, accessed February 6, 2026, [https://www.researchgate.net/publication/8941718\_The\_clinical\_use\_of\_HMG\_CoA-reductase\_inhibitors\_and\_the\_associated\_depletion\_of\_coenzyme\_Q\_10\_A\_review\_of\_animal\_and\_human\_publications](https://www.researchgate.net/publication/8941718_The_clinical_use_of_HMG_CoA-reductase_inhibitors_and_the_associated_depletion_of_coenzyme_Q_10_A_review_of_animal_and_human_publications)  
29. A Personalized Model of COQ2 Nephropathy Rescued by the Wild-Type COQ2 Allele or Dietary Coenzyme Q10 Supplementation \- PMC \- NIH, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5576924/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5576924/)  
30. COQ2 gene: MedlinePlus Genetics, accessed February 6, 2026, [https://medlineplus.gov/genetics/gene/coq2/](https://medlineplus.gov/genetics/gene/coq2/)  
31. Primary coenzyme Q10 deficiency: MedlinePlus Genetics, accessed February 6, 2026, [https://medlineplus.gov/genetics/condition/primary-coenzyme-q10-deficiency/](https://medlineplus.gov/genetics/condition/primary-coenzyme-q10-deficiency/)  
32. Primary Coenzyme Q10 Deficiency: An Update \- MDPI, accessed February 6, 2026, [https://www.mdpi.com/2076-3921/12/8/1652](https://www.mdpi.com/2076-3921/12/8/1652)  
33. Atherosclerosis and Coenzyme Q10 \- PMC, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6834161/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6834161/)  
34. Safety assessment of coenzyme Q10 (CoQ10) \- PubMed, accessed February 6, 2026, [https://pubmed.ncbi.nlm.nih.gov/19096117/](https://pubmed.ncbi.nlm.nih.gov/19096117/)  
35. (PDF) Atherosclerosis and Coenzyme Q10 \- ResearchGate, accessed February 6, 2026, [https://www.researchgate.net/publication/336577897\_Atherosclerosis\_and\_Coenzyme\_Q10](https://www.researchgate.net/publication/336577897_Atherosclerosis_and_Coenzyme_Q10)  
36. 2 Weeks of Ubiquinol Cuts LDL by 12% \- SupplySide Supplement Journal, accessed February 6, 2026, [https://www.supplysidesj.com/heart-health/2-weeks-of-ubiquinol-cuts-ldl-by-12-](https://www.supplysidesj.com/heart-health/2-weeks-of-ubiquinol-cuts-ldl-by-12-)  
37. A randomized, double-blind trial on the bioavailability of two CoQ10 formulations, accessed February 6, 2026, [https://www.researchgate.net/publication/271883127\_A\_randomized\_double-blind\_trial\_on\_the\_bioavailability\_of\_two\_CoQ10\_formulations](https://www.researchgate.net/publication/271883127_A_randomized_double-blind_trial_on_the_bioavailability_of_two_CoQ10_formulations)  
38. Research Article Impact of Oral Ubiquinol on ... \- Semantic Scholar, accessed February 6, 2026, [https://pdfs.semanticscholar.org/2b92/4c5960c9cde502c528477946bac95f33ca49.pdf](https://pdfs.semanticscholar.org/2b92/4c5960c9cde502c528477946bac95f33ca49.pdf)  
39. Comparative Bioavailability of Different Coenzyme Q10 Formulations in Healthy Elderly Individuals \- MDPI, accessed February 6, 2026, [https://www.mdpi.com/2072-6643/12/3/784](https://www.mdpi.com/2072-6643/12/3/784)  
40. Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial \- PMC, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4176102/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4176102/)  
41. Coenzyme Q10 \- StatPearls \- NCBI Bookshelf, accessed February 6, 2026, [https://www.ncbi.nlm.nih.gov/books/NBK531491/](https://www.ncbi.nlm.nih.gov/books/NBK531491/)  
42. Reduced Cardiovascular Mortality 10 Years after Supplementation with Selenium and Coenzyme Q10 for Four Years: Follow-Up Results of a Prospective Randomized Double-Blind Placebo-Controlled Trial in Elderly Citizens | PLOS One \- Research journals, accessed February 6, 2026, [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141641](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141641)  
43. Hathcock \- Bioactives, accessed February 6, 2026, [https://www.jhnfa.org/IADSA-3.pdf](https://www.jhnfa.org/IADSA-3.pdf)  
44. Getting better at aging \- Contentstack, accessed February 6, 2026, [https://eu-assets.contentstack.com/v3/assets/blt2183a7e3152cc969/blt73b2687f3aa106e0/66ed8c520eb0c01e01ed1c8e/SSSJ-Snapshot-Kaneka-0924-2641069.pdf](https://eu-assets.contentstack.com/v3/assets/blt2183a7e3152cc969/blt73b2687f3aa106e0/66ed8c520eb0c01e01ed1c8e/SSSJ-Snapshot-Kaneka-0924-2641069.pdf)  
45. CoQ10 and Aging \- PMC \- NIH, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6627360/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6627360/)  
46. Risk Assessment of "Other Substances" – Coenzyme Q10, accessed February 6, 2026, [https://journalejnfs.com/index.php/EJNFS/article/view/15](https://journalejnfs.com/index.php/EJNFS/article/view/15)  
47. Risk assessment for coenzyme Q10 (Ubiquinone) \- Ovid, accessed February 6, 2026, [https://www.ovid.com/journals/rtaph/pdf/10.1016/j.yrtph.2006.05.006\~risk-assessment-for-coenzyme-q10-ubiquinone](https://www.ovid.com/journals/rtaph/pdf/10.1016/j.yrtph.2006.05.006~risk-assessment-for-coenzyme-q10-ubiquinone)  
48. Coenzyme Q10: what is known about the health risks – and what isn't? \- BfR, accessed February 6, 2026, [https://www.bfr.bund.de/en/release/coenzyme-q10-what-is-known-about-the-health-risks-and-what-isnt/](https://www.bfr.bund.de/en/release/coenzyme-q10-what-is-known-about-the-health-risks-and-what-isnt/)  
49. Primary Coenzyme Q10 Deficiency Overview \- GeneReviews® \- NCBI Bookshelf, accessed February 6, 2026, [https://www.ncbi.nlm.nih.gov/books/NBK410087/](https://www.ncbi.nlm.nih.gov/books/NBK410087/)  
50. Coenzyme Q10 and Degenerative Disorders Affecting Longevity: An Overview \- MDPI, accessed February 6, 2026, [https://www.mdpi.com/2076-3921/8/2/44](https://www.mdpi.com/2076-3921/8/2/44)

[image1]: <data:image/png;base64,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>

[image2]: <data:image/png;base64,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>

[image3]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAADAAAAAYCAYAAAC8/X7cAAADEUlEQVR4Xu2XW8iMURSGX6HI+UyRP6QcLpyVkIQoSiGElHIIN0iO6Y9cUISUHBJKEpILkQsJIW65ccghcSGUcEHhfa29Z/bs7/tm5vP3R5q3nmZmrz17vrXXWnvtAWqqqVHVmkwgs8kA0tSNtyI93fuGqBOZguT6DdZAcpd8JmfJWnKKXCODyBUyqTA7n5qQ8eQ+bJ0FjuvkKRlZnJpfzclW8o1sJC1LzRhHPpHX+LMIaP1d5DmSDyrbEfKRDI1sVUkLHCLfyazI5tWCXHbofR759T+QUZHNazDMgYOwSOXSCvKTbEL5L58km+PBKqT1f7jXLPUgL8kj0jmylVU/8oY8Ib0iW6xjyM7/bmQGrDBV6F5+/YekazAeyzsg9L5q1cN2f2c0nqZ2sHQI1Z2cJxfJPLIelucjnL0etr5ey0l1pfrK5YCOyhuw8GbtbDn1hu2sCtA7phQ8Ta6SLrD1VVtjnT1LsmveLdImsmXKh+0t6RPZKqkZLKWUHkqTUKoVrTvEvVazqxuQjFRbWER3kKlIqc88eacCHBN8VvN5D0sfOePlT6vQgUq7qtS8R97Beo2kY3wL6Qh7cDky19kK6kAeoLID6prHUVqEKljt2PJgTFIkFdEzsPrQqfIMVuRZWghL43XBWH9yGMXUVO9YWTQXtQf2ZYUoTfJe3TjuD9NgDsiRUIqUcnkyLDJyROe7znk9jNJBXVe/q8/qC7KHdST5qKhrDye7kdHkVIiPyU3YjoVSGLeRNUjmn45cHb2rgzGFX7utnfTz9aP+AeeTOW58EVlFXpC9SHZ+SWn6CrbB25E+57fqyB3ylZwgi8l+WO5ORPLhvRQFHX3nHErHtPkKv5xVZHRc6/5zCRYJP1+XuTgC6t5KpSWwK84+JNcuSIY6MtPRF9XdEPWjyu/2sSGS5qk36PaptFuG0t4z3dm95GQY3dHkNnJ26caUdvULLN0OkAsoTRHfFL20SUq1vPewRpM/BIRqJL7kKYV0nV8KK+KjZFjJjL8s3Zd0edTu6z9ImpTWOsJ1xP8zO1/Tf6NfkoGWUzZztzMAAAAASUVORK5CYII=>

[image4]: <data:image/png;base64,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>

[image5]: <data:image/png;base64,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>

[image6]: <data:image/png;base64,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>

[image7]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAWCAYAAAD5Jg1dAAAA/klEQVR4Xs3SsUtCURTH8SMSmBIKheDQom7NKYU0tDm06JyL+CeoFG3NLro46NBS0D9gY/9CgVN/QEObtNf3vPve83pEcfQHH3j33Pse5533RPYyB7jCDY7NXpxzvKKNFj5Wt13O8IysV+t710EOMUbZ1O/NWi7QMzW9+c3U5AE1pFBADk0xPWYwwiW+8Rf6RcU7J0UMkBD3JH1iGo948c7tfrCOjl8IowPXVuLciRu0TQOLaBG9yEm8vcwQ82ih/eknO4q3XU7xJa7PINrfD6pRQdygJ5iJ9zl10Ld4xxOm+ERX3A1B/P6SyIv7rXRMK/HntzWb5reWa5Rs0eYfQSIkCUKj4rkAAAAASUVORK5CYII=>

[image8]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAwAAAAZCAYAAAAFbs/PAAAA20lEQVR4Xu3RL4sCQRzG8Z94giaDf0FFDAa7UTgxaTAr+AIsNoPBeyXHidGgYBDkXoKYDYLBYrUc2AT9jjNzzlrEZtgHPrA8v9nZ3VkRP++aFJqoIuwdeZPGDHO0McQBZTPPoGiuJY8NvhEy3Qcm+EUEX6jYwY/o3Qpmsc0Af6hjjKgqX76hhKPo91c3u+ngJHpxy5bqRC7o2sKJnS1Ef8ctDVOq4WNUd8anW+awQ8/pAqhhK/fNsojbBWq4xxQjrNBHAkusRR+vOv7/BJFETPQT3F7tbP+Pn6e5ApPEJUHhfTdnAAAAAElFTkSuQmCC>

[image9]: <data:image/png;base64,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>

[image10]: <data:image/png;base64,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>

[image11]: <data:image/png;base64,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>

[image12]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAADYAAAAYCAYAAACx4w6bAAADeElEQVR4Xu2XW8hOWRjHH6FoHNLIjBr5HG4cCs0pGpIkColxIUQuUOZmZi5maEafNBeTCCmSMFxIjTIXkkOTKCNuSTnkkMaFUGIKMf4/z1rv3nvt/e6PcvPW+69f797rvPZ6Dus1a6utllAfMVV8K0aJ7qH8I/FZeE7VU4wx7zND9C9W1+pj8z7pfB9Mo8U/4qk4LH4QB8RJ80UfF9MbrV39xCZxU/xivjh+H4by3lnTgrqJKeKi+biLA3+LG+LLrGlDg8WvYrfYIEYWq8via7OYF+JnKy9msngi7lnxxMaL62KLlft8JR6LnaJHUsd8v4tbVt4AdSycvhNy5Yx3ynwt48Qx8b/40fwjlcRATP5SLEjqonqZDwQ8oy/EA/NFMEaVtpsvcGyuLM73yHyxVaI9/XaYL5qPdlSssMxMMV9O+5n4PJQVtNp852utyc6D/hDrwvMgcTnAczNhWoy9KlfGfK/DbzNhcnfEFTEw947VcFpRrIfxcZmCsNF/zc1pSFKXao+5f7H5jeYDfldoUVbc2E/hPc7X1QeJGwGeOeVt4kR4j2Lc/PgNdZpX/JaUV4koxwTDzH3tvhheaFEW4+Yn7gzv/NYJP2aOuLEq4bd/ilfmEbwhQvoZc7NII12d5povLu9vVYp+Sdv5ls2HL3+TNasU9bQ7J/omdVFfm/tXycfjcb/Ll88rHj+BoU7kI0I+X55TTs2rTnGOzqQ8Cus5LQ6a59aC3mciHH1SeG5q14liu63mfhnnqzsFxKIvmEdccmcqTmeXVaeYtxogLlnXGyOs7rXM2YlwXW2swzxhX7Us7xHdiHKUfxLKqrTE3D3IT6nipojgMexjGdxaCtpsPsjMtCKIL00ozee3ieK5ueOmiRflE2w+T9H2UCgnT9GO6Motg3XwHpN6yW/M18Jmvw/PUXxofLigoeKaOCs+Teo45vVWHogFkmBxXBw4L+x9n7ht5RsF4iYRF75ILAzlS8Ua835VJsb8y8V/5j57NweJvjIYdYjz5p32i2XmOQNfmGbVSZuJuQfSh5Ae74dMRFDh/thMbJi8SdSjL7nuL/OTi/NhZvkTi/6JC6TUBj8G6xDzAiPs3W7YOHq8lWNGdeE/LxbNlYx+c8RKK+bS2aG+5cUdENPGhzjxI1Y2x5bULMtMKw06LS2CDiGc0+I/YVtttbreAJp7w+SpvzcKAAAAAElFTkSuQmCC>

[image13]: <data:image/png;base64,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>

[image14]: <data:image/png;base64,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>

[image15]: <data:image/png;base64,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>

[image16]: <data:image/png;base64,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>

[image17]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAVCAYAAAB/sn/zAAAAuUlEQVR4Xu3QPQ4BURSG4StIJMRPJUJDYQcqCq0EG7AArR0IiVpiB3qFBYhMQmEJGvHT6PQq3mPmcDK1RONLnmLO/ZK59zj3z7cTRx3J0DyLhB10cUcj+K5iiwfmWpJMcEIJbQxRwwYtLaXgYY0peojooU0FV9xwwR4jpG1JEr5fGbtARksSvV/RzGY4II+mDGQdKywQe9f8l3rO//1YBgWc0f90XungiCUGMpDX5RA1JY1sQxb+yzwBlNwcggIBTdAAAAAASUVORK5CYII=>

[image18]: <data:image/png;base64,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>

[image19]: <data:image/png;base64,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>

[image20]: <data:image/png;base64,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>

[image21]: <data:image/png;base64,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>

[image22]: <data:image/png;base64,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>